DiappyMed

What DiappyMed does

DiappyMed is a French medtech company founded in January 2021 in Clapiers (near Montpellier) that develops digital therapeutics for personalized diabetes management. Its core product, EkiYou, is a CE-marked Class IIb medical device under MDR (EU) 2017/745 that calculates personalized insulin bolus doses for adults with type 1 or type 2 diabetes on basal-bolus insulin regimens. The algorithm ingests blood glucose, insulin-on-board, carbohydrate ratios, correction factors, physical activity, and entries from a proprietary food database of more than 400,000 verified foods sourced from CIQUAL (ANSES), and integrates with continuous glucose monitors including Dexcom. A companion consumer product, EkiYou Carbs, is a mobile carb-counting application distributed on iOS and Android in nine countries (France, Belgium, Luxembourg, Switzerland, Lebanon, Tunisia, Algeria, Morocco, and Canada), with a freemium model and a €6.99/month premium subscription. Both products share the same food database and were co-constructed with a medical committee of recognized experts and more than 2,000 patients; clinical efficacy is documented in the GLUCAL (NCT02676609) and GLUCAL3 (NCT05098301) studies published in Diabetes Technology & Therapeutics, showing a +5.75% improvement in postprandial glycemia within target range and a 24% reduction in daily correction boluses.

The business operates a dual revenue model: EkiYou is prescribed by diabetologists and endocrinologists via the AppThera digital therapy platform with 3-month initial and 6-month renewal prescriptions, currently targeted for French national health insurance reimbursement by 2026; EkiYou Carbs generates consumer subscription revenue and access-code distribution through home health providers (PSADs) including Bastide and Asdia. The company holds ISO 13485 quality certification, HDS health data hosting certification, and GDPR compliance, and operates with a team of approximately 18 people across product, IT, regulatory, data science, business development, and marketing functions.

In March 2026 DiappyMed closed a €5 million seed round co-led by Ventech and AFI Ventures (with SOFILARO and IRDI Capital Investissement) and simultaneously announced a strategic partnership with Sanofi to deploy EkiYou to healthcare professionals and patients nationwide in France. The capital and partnership are directed toward accelerating HCP adoption and securing Assurance Maladie reimbursement, which the company identifies as the primary inflection point for scaling prescription volumes across France's 3.8 million diabetic population.

Name

DiappyMed

Legal name

DIAPPYMED

Website

https://diappymed.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

DiappyMed is a French medtech founded in 2021 that develops EkiYou, a CE-marked Class IIb digital therapy calculating personalized insulin doses for type 1 and type 2 diabetics, plus a companion consumer carb-counting app, distributed via prescription in France and app stores across nine countries.

Ownership category

akta.pro rank

Product category

Digital Therapeutics for Diabetes Management

akta.pro primary industry

Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators) (HLAHAHAJ)

akta.pro secondary industry

Automated Insulin Delivery (AID) / Closed-Loop Systems (HLAHAHAF)

Keywords

• Digital therapeutics
• Diabetes management software
• Insulin dose calculation
• Carb counting app
• CE-marked medical device

Headquarters

HQ city

Clapiers

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. EkiYou Prescription Digital Therapy: CE-marked Class IIb medical device requiring prescription. Available through 3-month initial prescription and 6-month renewal prescriptions. Revenue generated through healthcare system reimbursement (targeting national health insurance coverage) and direct patient subscriptions.
2. EkiYou Carbs Premium Subscription: Mobile app with freemium model - basic version free with 4,000 foods, premium subscription at €6.99/month for full 400,000+ food database access. Alternative access via codes from home health providers.

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels6 records

Core offering

DiappyMed develops and sells digital therapeutic software for diabetes management, principally EkiYou, a CE-marked Class IIb medical device that calculates personalized insulin bolus doses for adults with type 1 or type 2 diabetes on basal/bolus regimens by processing blood glucose, on-board insulin, food intake from a 400,000+ item CIQUAL-sourced database, and physical activity. The company also offers EkiYou Carbs, a freemium companion mobile app for carbohydrate counting and nutrition information available without prescription across 9 countries.

Product overview

DiappyMed offers two digital health products for diabetes management: EkiYou (the core product) is a CE-marked Class IIb digital therapy requiring a prescription that calculates personalized insulin doses based on meals, physical activity, and blood glucose levels; EkiYou Carbs is a companion mobile app focused on carbohydrate counting and nutrition information that is available without prescription across 9 countries. Both products share a common food database of over 400,000 verified foods based on the CIQUAL database, and both are accessible via iOS and Android devices. EkiYou targets patients on multiple daily insulin injections (basal/bolus regimen) seeking personalized insulin therapy support, while EkiYou Carbs serves a broader audience including those with type 1 and type 2 diabetes who want simplified carb counting.

Differentiator

Problem solved

Functional benefit

Brands

• EkiYou: CE-marked Class IIb digital therapy (DTx) for calculating personalized insulin doses based on meals, physical activity, and blood glucose levels. France's first digital therapy for personalized insulin dosing.
• EkiYou Carbs

Products and services

• EkiYou EkiYou is a CE-marked Class IIb digital therapy (medical device) that calculates personalized insulin bolus doses for adults with type 1 or type 2 diabetes treated with a basal/bolus insulin regimen. It processes blood glucose, on-board insulin, carbohydrate intake from over 400,000 verified foods, and physical activity to generate dose recommendations. Available by prescription only in France (3-month initial prescription, 6-month renewal), with national health insurance reimbursement targeted for 2026.
• EkiYou Carbs EkiYou Carbs is a mobile nutrition information and carbohydrate-counting application for people with diabetes to simplify daily carb counting. Features include a food database of over 400,000 foods (4,000 free), barcode scanning, visual portion indicators, AI-powered meal photo analysis, and logbook export. Available without prescription across 9 countries on iOS and Android. Premium subscription at €6.99/month or access codes from home health providers.

Quantifiable outcome

• +5.75% improvement in postprandial glycemia within target range (GLUCAL study NCT02676609)
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability6 records

Feature5 records

Partnerships

Five partnerships are on record, tiered core and minor.

• SanoficoreStrategic or Co-development Partner · 23 March 2026Strategic partnership announced March 2026 for nationwide deployment of EkiYou digital therapy to healthcare professionals and patients. Sanofi hosted DiappyMed at SFD congress stand to showcase personalized insulin dosage application. Partnership aimed at accelerating deployment and obtaining social security reimbursement.
• AppTheracoreTechnology or IntegrationDigital therapy prescription platform partner enabling healthcare professionals to prescribe EkiYou and patients to receive access codes digitally.
• BastideminorChannel Partner/ Reseller/ DistributorHome health provider (PSAD - Prestataire de Sante a Domicile) distributing EkiYou Carbs access codes to patients.
• AsdiaminorChannel Partner/ Reseller/ DistributorHome health provider (PSAD) partner distributing EkiYou Carbs premium access codes.
• Montpellier University Hospital (CHU Montpellier)coreStrategic or Co-development PartnerClinical research partnership origin. GLUCAL and GLUCAL3 studies conducted at CHU Montpellier under Prof. Eric Renard. Product co-constructed with medical committee including CHU Montpellier doctors.

Scale indicators9 records

Recent moves5 records

Expansion highlights7 records

Direct peers

• Voluntis (Aptar Digital Health): Develops prescription digital therapeutics for insulin dose adjustment and chronic disease management. Most direct competitor to DiappyMed's EkiYou in regulated, prescriber-driven insulin titration software.
• Hedia: Danish DTx startup offering an insulin dosing calculator for Type 1 and Type 2 diabetes patients on basal/bolus regimens, with CGM integration. Closely comparable product targeting the same insulin pen user segment.
• DreaMed Diabetes (Insulet): Algorithm-based insulin dosing decision support (DreaMed Advisor) now part of Insulet. Direct comparable in automated insulin dose recommendation technology, though primarily oriented toward pump users.
• mySugr (Roche Diabetes Care): Diabetes self-management app with carb counting, bolus estimation, and CGM integration, now part of Roche. Closely comparable consumer-side companion to a regulated insulin dosing product.

Broad incumbents

• Tandem Diabetes Care: Insulin pump maker (t:slim X2) with embedded bolus calculator and Control-IQ AID algorithm. Adjacent category player with overlapping prescriber relationships and bolus dose decision support.
• Medtronic Diabetes: Largest integrated diabetes platform (MiniMed pumps, Guardian CGM, AID systems). Broad incumbent competing for the same endocrinologist prescribers and patient populations in Europe.
• Insulet Corporation: Omnipod tubeless insulin pump maker with bolus calculator. Acquired DreaMed Diabetes, giving it algorithmic insulin dosing capability that could extend into pen-user segments.
• Dexcom: Leading CGM manufacturer and current integration partner of EkiYou. As CGM becomes the data backbone of diabetes DTx, Dexcom's platform reach and own software initiatives (e.g., Dexcom Clarity, Stelo) make it both a partner and a competitor.
• Roche Diabetes Care: Provides Accu-Chek blood glucose meters and mySugr app; a broad diabetes management incumbent with potential to extend into DTx-style dosing support for its installed base.
• LifeScan: Blood glucose monitoring company (OneTouch) with digital diabetes management ambitions. Adjacent incumbent whose meter ecosystem overlaps with DiappyMed's pen-user insulin therapy workflows.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@DiappyMedapp
• Facebookfacebook.com/DiappyMed
• LinkedInlinkedin.com/company/diappymed
• Instagraminstagram.com/diappymed

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DiappyMed